Mediphage Bioceuticals is developing msDNAᵀᴹ, a novel plasmid technology that enhances the quality of genetic medicines by minimizing immunogenicity and reducing the risk of insertional mutagenesis. This platform enables the production of high-fidelity DNA for various applications, including gene therapies for chronic and genetic diseases.
Funding
$4.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The production of genetic medicines relies on DNA plasmids, which can present challenges related to immunogenicity, risk of insertional mutagenesis, and fidelity during replication. Conventional DNA vectors often contain unnecessary backbone sequences that increase the risk of immunogenicity. Circular DNA vectors carry a higher risk of insertional mutagenesis, while enzymatic DNA replication methods can introduce mutations, affecting the quality and yield of final pharmaceutical products.
Solution
Mediphage Bioceuticals offers msDNAᵀᴹ, a novel linear, minimized plasmid technology designed to improve the safety and efficacy of genetic medicines. msDNAᵀᴹ eliminates unnecessary backbone sequences, reducing the risk of immunogenicity and potential negative impacts on drug product quality. Its linear topology reduces the risk of insertional mutagenesis compared to circular vectors. Manufactured using an _E. coli_ fermentation process, msDNAᵀᴹ exhibits higher fidelity with significantly fewer loss-of-function mutations compared to enzymatic production methods. This platform serves as a versatile tool for various applications, including gene addition, _in vivo_ gene editing, DNA vaccines, _ex vivo_ cell therapy, and the production of mRNA, lentiviral, and rAAV vectors.
Target Audience
Mediphage's primary customers include companies developing gene therapies, DNA vaccines, _ex vivo_ cell therapies, and viral vectors, as well as researchers in the field of genetic medicine.
Features
- Linear topology to reduce the risk of insertional mutagenesis
- Minimized sequence to lower immunogenicity
- High-fidelity production using an _E. coli_ fermentation process
- Super Sequences (SSeq) to enhance cellular trafficking and nuclear uptake
- Demonstrated prolonged and durable gene expression after a single systemic injection
- Increased tolerability and redosability
- In-built safety switch to prevent potentially oncogenic chromosomal integration
- Customizable to accommodate large mono- or poly-cistronic genetic payloads up to 20-25 kb